CCL20 Antikörper

Produktnummer ABIN192395

Der Maus Monoklonal Anti-CCL20-Antikörper wurde für IP, FACS, IHC (p) und IHC (fro) validiert. Er ist geeignet, CCL20 in Proben von Human zu detektieren. Es sind 6+ Publikationen verfügbar.

Kurzübersicht für CCL20 Antikörper (ABIN192395)

Target: CCL20 (Chemokine (C-C Motif) Ligand 20 (CCL20))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CCL20 Antikörper ist unkonjugiert

Applikation: Immunoprecipitation (IP), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Klon: UCHL1

Produktdetails anti-CCL20 Antikörper

Verwendungszweck: Anti-Hu CD45R0 Purified

Spezifität: The antibody UCHL1 recognizes an extracellular epitope of CD45R0, a 180 kDa low molecular weight isoform of the leukocyte common antigen (LCA). The antigen is expressed on a subset of memory/activated T cells and on cortical thymocytes.

Kreuzreaktivität (Details): Human

Aufreinigung: Purified by protein-A affinity chromatography.

Reinheit: > 95 % (by SDS-PAGE)

Immunogen: Human IL-2 dependent T cells

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: Immunohistochemistry (paraffin sections): This product does not require protein digestion pretreatment of paraffin sections. This product does not require antigen retrieval using heat treatment prior to staining of paraffin sections. Positive tissue: tonsil.
Immunohistochemistry (frozen sections): Positive tissue: tonsil.
Flow cytometry: Recommended dilution: 10 μg/mL.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Do not freeze.

Referenzen für anti-CCL20 Antikörper (ABIN192395)

Akbar, Terry, Timms, Beverley, Janossy: "Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 140, Issue 7, pp. 2171-8, (1988) (PubMed).

Beverley, Merkenschlager, Terry: "Phenotypic diversity of the CD45 antigen and its relationship to function." in: Immunology. Supplement, Vol. 1, pp. 3-5, (1988) (PubMed).

Terry, Brown, Beverley: "The monoclonal antibody, UCHL1, recognizes a 180,000 MW component of the human leucocyte-common antigen, CD45." in: Immunology, Vol. 64, Issue 2, pp. 331-6, (1988) (PubMed).

Beverley: "Human T cell subsets." in: Immunology letters, Vol. 14, Issue 4, pp. 263-7, (1987) (PubMed).

Norton, Ramsay, Smith, Beverley, Isaacson: "Monoclonal antibody (UCHL1) that recognises normal and neoplastic T cells in routinely fixed tissues." in: Journal of clinical pathology, Vol. 39, Issue 4, pp. 399-405, (1986) (PubMed).

Smith, Brown, Rowe, Callard, Beverley: "Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1." in: Immunology, Vol. 58, Issue 1, pp. 63-70, (1986) (PubMed).

Details zu CCL20

Target: CCL20 (Chemokine (C-C Motif) Ligand 20 (CCL20))

Andere Bezeichnung: CD45R0

Hintergrund: CD45R0 is the shortest isoform of a receptor-type protein tyrosine phosphatase, CD45 glycoprotein. CD45 is crucial in lymphocyte development and antigen signaling, serving as an important regulator of Src-family kinases, promotes cell survival by modulating integrin-mediated signal transduction pathway and is also involved in DNA fragmentation during apoptosis. CD45 isoforms differ in their extracellular domains, whereas they share identical transmembrane and cytoplasmic domains. These isoforms differ in their ability to translocate into the glycosphingolipid-enriched membrane domains and their expression depends on cell type and physiological state of the cell. CD45R0 is expressed e.g. on macrophages, CD8+ T cells, activated T cells and myeloma cells.,PTPRCR, T200R0

Pathways: Phosphorylierungen bei SARS-CoV-2 Infektion